Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001213900-24-085881
Filing Date
2024-10-07
Accepted
2024-10-07 15:46:09
Documents
83
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 10-Q ea0216727-10qa1_bioess.htm   iXBRL 10-Q/A 671141
2 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUAN ea021672701ex31-1_bioess.htm EX-31.1 17754
3 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUAN ea021672701ex32-1_bioess.htm EX-32.1 10673
4 GRAPHIC image_001.jpg GRAPHIC 7166
  Complete submission text file 0001213900-24-085881.txt   5378103

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE bioe-20240331.xsd EX-101.SCH 64416
6 XBRL CALCULATION FILE bioe-20240331_cal.xml EX-101.CAL 59314
7 XBRL DEFINITION FILE bioe-20240331_def.xml EX-101.DEF 257480
8 XBRL LABEL FILE bioe-20240331_lab.xml EX-101.LAB 457253
9 XBRL PRESENTATION FILE bioe-20240331_pre.xml EX-101.PRE 265266
87 EXTRACTED XBRL INSTANCE DOCUMENT ea0216727-10qa1_bioess_htm.xml XML 614766
Mailing Address 12 CHRYSLER UNIT B IRVINE CA 92618
Business Address 12 CHRYSLER UNIT B IRVINE CA 92618 949-706-9966
Bio Essence Corp (Filer) CIK: 0001723059 (see all company filings)

EIN.: 943349551 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 000-56263 | Film No.: 241357730
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)